Will CLCS receive FDA approval for any of its drug candidates in the next two years?
Resolves: CLCS receives FDA approval for one of its drug candidates.
sec_filing· Regulatory Approval
Will CLCS receive FDA approval for any of its drug candidates in the…
Market overview
Derived from Cell Source, Inc. (CLCS) (CIK 0001569340) 10-K filing analysis
Regulatory Approval prediction market
- Implied probability (Yes)
- 40%
- Closes
- 2027-04-07
About this prediction
Resolution criteria
CLCS receives FDA approval for one of its drug candidates.
More Regulatory Approval markets
- Favorable Regulatory Outcome for Business Combination — 80% Yes
- FDA Approval Anticipation for AEMD Products — 40% Yes
- FDA Approval of New Drug Candidate in Phase 3 Trials — 60% Yes
- Will the SEC declare the proxy statement effective by February 28, 2027? — 65% Yes
- New Product Regulatory Approval — 75% Yes
- Will the divestiture close by Q1 2027? — 85% Yes
No one's made a Conviction call on this yet. Be the first to call it →
Loading…